Skip to content

Functional and Value-Added Dairy Products and Blood Glucose Control

The Sensory and Metabolic Effects of Functional and Value-Added Dairy Products

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05400694
Enrollment
20
Registered
2022-06-01
Start date
2021-10-01
Completion date
2023-03-31
Last updated
2023-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Glucose, High, Metabolic Disease, Overweight and Obesity

Keywords

Sugar intake, Sweeteners, Milk Proteins, Diabetes, Obesity, Sweetened food products, Chocolate milk, Blood glucose, Insulin, Satiety, Food Intake, Casein, Whey protein

Brief summary

Milk proteins possess multiple biological activities including their effect on blood glucose control, satiety and energy intake. The design of functional food products with added milk protein fractions has many challenges related to their inferior sensory properties. Chocolate milk presents the universal vehicle for added milk protein fractions that might partially mask their sensory characteristics. However, commercially produced chocolate milk has a significant amount of added sugar. This project will investigate the properties of a value-added dairy product (chocolate milk with reduced sugar content) enriched with individual milk protein fractions on characteristics of blood glucose control, satiety and energy intake in young healthy adults.

Interventions

OTHERFood

Dairy products with reduced sugar content

Sponsors

University of Toronto
CollaboratorOTHER
Mount Saint Vincent University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Treatments are blinded.

Eligibility

Sex/Gender
ALL
Age
19 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* 19-35 y males and females, non-smokers

Exclusion criteria

* having any diseases, irregular menses in females, smoking (all types), taking medications known to influence blood glucose control, skipping breakfast, and having emotional, or learning problems that would affect their ability to participate in the study as required. Individuals with known food allergies and lactose intolerance will be also excluded.

Design outcomes

Primary

MeasureTime frameDescription
Blood glucose0-120 minutesThe concentration of blood glucose
Insulin0-120 minutesThe concentration of insulin

Secondary

MeasureTime frameDescription
Satiety0-120 minutesThe components of average subjective appetite including desire to eat, hunger, fullness, and a prospective food consumption measured with 100mm visual analogue scales.
Food Intake0 min, 120 minutesEnergy intake with an ad libitum meat at 120 minutes
C-peptide0-120 minutesThe concentration of C-peptide
Physical comfort0-120 minutesThe subjective feeling of wellness and gastrointestinal discomfort parameters including the feeling of nausea, stomach cramps, flatulency, diarrhea and a subjective feeling of wellness, each measured with 100mm visual analogue scales.
Food pleasantnessat 0 and 120 minutesThe perception of pleasantness of the treatments (0 minutes) and a test meal (at 120 minutes) will be measured with 100mm visual analogue scale.
Thirst0-120 minutesThe subjective perception of thirst measured with 100mm visual analogue scales containing the question How thirsty do you feel? and two statements on each pole of 100mm line: Not thirsty at all (0mm) and As thirsty as I have ever felt (100mm).
Incretins, glucagon and amino acids0-120 minutesThe concentration of incretins and glucagon

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026